How many 8-K filings has Biovie Inc. filed?

Biovie Inc. (BIVIW) has 21 8-K (Current Event Report) filings on record, spanning Jan 2024 to Nov 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Biovie Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Biovie Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Biovie Inc. (BIVIW) — 8-K Filings

All 8-K filings from Biovie Inc.. Browse 21 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (21)

BioVie Inc. Files 8-K on Officer/Director Changes & Compensation — Nov 13, 2025 Risk: medium
BioVie Inc. filed an 8-K on November 13, 2025, reporting on events as of November 10, 2025. The filing covers the departure of directors or certain officers, th
BioVie Inc. Files 8-K on Shareholder Vote Matters — Nov 12, 2025 Risk: medium
BioVie Inc. filed an 8-K on November 12, 2025, reporting on a submission of matters to a vote of security holders. The filing date is November 10, 2025. The com
BioVie Inc. Files 8-K: Material Agreement and Equity Sales — Aug 11, 2025 Risk: medium
BioVie Inc. announced on August 7, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity securitie
BioVie Inc. Reports Board Changes and Officer Appointments — Jul 23, 2025 Risk: medium
BioVie Inc. announced on July 17, 2025, a change in its board of directors, including the election of new directors and the appointment of certain officers. The
BioVie Inc. Reports Material Modification to Security Holder Rights — Jun 27, 2025 Risk: medium
BioVie Inc. filed an 8-K on June 27, 2025, reporting a material modification to the rights of its security holders as of June 26, 2025. The filing indicates a c
BioVie Inc. Files 8-K on Shareholder Vote Matters — Jun 24, 2025 Risk: low
BioVie Inc. filed an 8-K on June 24, 2025, reporting on matters submitted to a vote of its security holders as of June 23, 2025. The company, formerly known as
BioVie Inc. Relocates HQ, Reports Officer & Director Changes — Mar 28, 2025 Risk: medium
BioVie Inc. announced on March 28, 2025, a change in its principal executive offices to 680 W Nye Lane, Suite 201, Carson City, NV 89703. The company also repor
BioVie Inc. Files 8-K on Shareholder Vote Matters — Nov 8, 2024 Risk: medium
BioVie Inc. filed an 8-K on November 8, 2024, reporting on a submission of matters to a vote of security holders as of November 7, 2024. The company, formerly k
BioVie Inc. Files 8-K: Material Agreement & Equity Sales — Oct 29, 2024 Risk: medium
BioVie Inc. announced on October 28, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity securit
BioVie Inc. Files 8-K: Material Agreement, Equity Sales — Oct 24, 2024 Risk: medium
BioVie Inc. filed an 8-K on October 24, 2024, reporting on events as of October 23, 2024. The filing indicates a material definitive agreement, unregistered sal
BioVie Inc. Files 8-K: Material Agreement & Equity Sales — Oct 22, 2024 Risk: medium
BioVie Inc. announced on October 21, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity securit
BioVie Inc. Files 8-K with Financials and Disclosures — Sep 25, 2024 Risk: medium
BioVie Inc. filed an 8-K on September 25, 2024, reporting on various events and financial statements. The company, formerly known as NanoAntibiotics, Inc., is i
BioVie Inc. Files 8-K Under 'Other Events' — Aug 21, 2024 Risk: low
BioVie Inc. filed an 8-K on August 21, 2024, reporting an event that occurred on August 20, 2024. The filing is categorized under 'Other Events' and does not sp
BioVie Inc. Files 8-K on Security Holder Rights and Bylaws — Aug 1, 2024 Risk: medium
On July 29, 2024, BioVie Inc. filed an 8-K report detailing material modifications to security holder rights and amendments to its articles of incorporation. Th
BioVie Inc. Appoints New CMO, Elects Directors — Jul 30, 2024 Risk: medium
BioVie Inc. announced on July 25, 2024, the appointment of Dr. Babak B. Moussavi as Chief Medical Officer and the election of Dr. Moussavi and Ms. Sarah E. Empe
BioVie Inc. Faces Delisting Concerns — Apr 19, 2024 Risk: high
BioVie Inc. filed an 8-K on April 19, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, formerly kn
BioVie Inc. Files 8-K — Mar 11, 2024 Risk: low
BioVie Inc. filed an 8-K on March 11, 2024, reporting on other events and financial statements. The company, formerly known as NanoAntibiotics, Inc., is incorpo
BioVie Inc. Files 8-K with Corporate Updates — Mar 6, 2024 Risk: low
BioVie Inc. filed an 8-K on March 6, 2024, reporting on various events and financial statements. The filing indicates the company's principal executive offices
BioVie Inc. Files 8-K Report — Mar 1, 2024 Risk: low
BioVie Inc. filed an 8-K on March 1, 2024, reporting other events and financial statements. The company, formerly known as NanoAntibiotics, Inc., is incorporate
BioVie Files 8-K on Jan 19 Event; Confirms Nasdaq Listing — Jan 25, 2024
BioVie Inc. filed an 8-K on January 25, 2024, reporting an 'Other Event' that occurred on January 19, 2024. This filing primarily updates administrative informa
BioVie Files Routine 8-K, Confirms Nasdaq Listing — Jan 19, 2024
This 8-K filing from BioVie Inc. on January 19, 2024, is a routine administrative update, primarily confirming its status as a publicly traded company on The Na

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX